drugset / Trial / NCT03911557
Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study will examine whether patients with relapsed/refractory solid tumors harboring evidence of somatic hypermutation (intermediate versus high tumor mutational burden) will exhibit improvement in disease progression-free survival with dual Tremelimumab and Durvalumab treatment.
Timeline
- Start
- 2019-06-08
- Primary completion
- 2025-10-10
- Completion
- 2025-10-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 75 mg | Intravenous |
Indications
No indication recorded.